Pharming Group N.V.

318 articles about Pharming Group N.V.

• Pharming Group And CytoBioteck Announce Extension Of Distribution Agreement For Ruconest

  2/9/2016

• Pharming Group Announces Completion Of Patient Enrolment In Clinical Study Of Ruconest For Prophylaxis Of Hereditary Angioedema

  1/6/2016

• Pharming Group Release: European Medicines Agency Reaffirms Important Health Benefits And Safety Of Ruconest For Patients With Hereditairy Angioedema

  12/7/2015

• Pharming Group Release: Interim Report January - September 2015

  10/28/2015

• Pharming Group Nominates Mr Robin Wright As Chief Financial Officer

  9/8/2015

• Pharming Group Reports On Financial Results First Half Year 2015

  7/30/2015

• Pharming Group Release: HAEi Global Access Program for RUCONEST Now Live

  7/21/2015

• Pharming Group Announces Us$17 Million (€15.6 Million) Straight Debt Financing

  7/20/2015

• Pharming Group Announces Interim Results From The Ongoing Phase II Pediatric Clinical Trial Of Ruconest

  6/1/2015

• Pharming Group And Clinigen Group Initiate "Haei GAP" Global Access Program For RUCONEST

  5/18/2015

• Pharming Group Reports On Financial Results For Q1 2015

  4/30/2015

• Pharming Group Nominates Paul Sekhri And Jan Egberts As Members Of Its Board Of Supervisory Directors

  3/19/2015

• Pharming Group Appoints Dr. Perry Calias As Chief Scientific Officer

  2/18/2015

• Pharming Group And Salix Pharmaceuticals, Ltd. Announce First Patient Treated In Clinical Study Of Ruconest® For Prophylaxis Of Hereditary Angioedema

  1/8/2015

• Pharming Group Confirms Receipt Of US$20 Million Milestone Payment From Salix Pharmaceuticals, Ltd.

  11/4/2014

• Pharming Group And Salix Pharmaceuticals, Ltd. Announce The Launch Of Ruconest® In The U.S. For The Treatment Of Acute Angioedema Attacks In Patients With Hereditary Angioedema (HAE)

  11/3/2014

• Pharming Group Reports On Financial Results For The First Nine Months Of 2014

  10/30/2014

• Pharming Group And Swedish Orphan Biovitrum Amend And Extend Ruconest Distribution Agreement

  10/13/2014

• Pharming Group And Salix Pharmaceuticals, Ltd. Announce Initiation Of Clinical Study Of Ruconest® For Prophylaxis Of Hereditary Angioedema

  8/28/2014

• Pharming Group Acquires New Product Leads Through The Acquisition Of Certain Assets Of TRM SASU For € 0.5 Million In Cash

  8/19/2014